AChR Binding Antibody Test in Hawaii

What this test measures

Myasthenia gravis is an autoimmune condition in which the immune system produces antibodies against proteins at the neuromuscular junction. The most common target is the acetylcholine receptor, a structure on the muscle side of the junction that receives nerve signals. Detecting these antibodies gives clinicians an objective clue when someone reports fluctuating weakness, drooping eyelids, or difficulty with speech and swallowing.

The binding antibody assay is the standard first step and is positive in a large share of people with generalized myasthenia gravis. When binding antibodies are not detected but the clinical picture still suggests the condition, laboratories may add blocking or modulating antibody tests, or related markers such as muscle-specific kinase antibodies. The test requires only a blood sample.

Results do not stand alone. Some people with the condition test negative on available antibody assays, and antibodies can occasionally appear in other settings. Clinicians combine the laboratory result with symptoms, examination findings, and sometimes electrical or imaging studies before reaching a conclusion.